This article is more than 5 years old. Information may no longer be current.

Imprimis launching Surface Pharmaceuticals subsidiary

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Imprimis Pharmaceuticals has filed a Form 8-K with the SEC to launch a subsidiary called Surface Pharmaceuticals Inc., according to an Imprimis press release.

Surface Pharmaceuticals will seek FDA approval for three drug candidates for up to five indications for ocular surface diseases, including dry eye and blepharitis, the release said.

The subsidiary will be managed and funded outside of Imprimis, and Imprimis expects Kamran Hosseini, MD, PhD, to be the CEO of Surface, once it is funded. Surface’s board will be chaired by OSN Chief Medical Editor Richard L. Lindstrom, MD, and include Adrienne Graves, PhD, and Louis Drapeau.